Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

PURPOSE Anti-HER2 immunoliposomes combine the tumor-targeting of certain anti-HER2 monoclonal antibodies (MAbs) with the pharmacokinetic and drug delivery capabilities of sterically stabilized liposomes. We previously showed that anti-HER2 immunoliposomes bind efficiently to and internalize in HER2-overexpressing cells in vitro, resulting in intracellular drug delivery. EXPERIMENTAL DESIGN Here we describe the pharmacokinetics and therapeutic efficacy of anti-HER2 immunoliposomes containing doxorubicin (dox) in a series of animal models. RESULTS Immunoliposomes displayed long circulation that was identical to that of sterically stabilized liposomes in single- and multiple-dose studies in normal rats. Anti-HER2 immunoliposome-dox produced marked therapeutic results in four different HER2-overexpressing tumor xenograft models, including growth inhibition, regression, and cures. These results demonstrated that encapsulation of dox in anti-HER2 immunoliposomes greatly increased its therapeutic index, both by increasing antitumor efficacy and by reducing systemic toxicity. Immunoliposome-dox was significantly superior to all other treatment conditions tested, including free dox, liposomal dox, and anti-HER2 MAb (trastuzumab). When compared with liposomal dox in eight separate therapy studies in HER2-overexpressing models, immunoliposome delivery produced significantly superior antitumor efficacy in each study (P < 0.0001 to 0.04). Anti-HER2 immunoliposome-dox containing either recombinant human MAb HER2-Fab' or scFv C6.5 yielded comparable therapeutic efficacy. Cure rates for immunoliposome-dox reached 50% (11 of 21) with optimized immunoliposomes and Matrigel-free tumors and overall was 16% (18 of 115) versus no cures (0 of 124) with free dox or liposomal dox. Finally, anti-HER2 immunoliposome-dox was also superior to combinations consisting of free MAb plus free dox or free MAb plus liposomal dox. CONCLUSIONS Anti-HER2 immunoliposomes produced enhanced antitumor efficacy via targeted delivery.

[1]  P. Carter,et al.  Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. , 1992, Cancer treatment and research.

[2]  Y. Barenholz,et al.  Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.

[3]  D A Berry,et al.  erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. , 1998, Journal of the National Cancer Institute.

[4]  F. Martin,et al.  Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. , 1992, Cancer research.

[5]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[6]  John W. Park,et al.  Immunoliposomes for cancer treatment. , 1997, Advances in pharmacology.

[7]  M. Sznol,et al.  Antigen-specific agents in development. , 1997, Seminars in oncology.

[8]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.

[9]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[10]  D Tripathy,et al.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  T. Allen,et al.  Long-circulating, polyethylene glycol-grafted immunoliposomes , 1996 .

[12]  J. Huston,et al.  In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. , 1995, Immunotechnology : an international journal of immunological engineering.

[13]  D. Heitjan.  Generalized Norton-Simon models of tumour growth. , 1991, Statistics in medicine.

[14]  J. Seidman,et al.  Expression of the HER‐2/neu proto‐oncogene in serous ovarian neoplasms , 1992, Cancer.

[15]  A. Gabizon,et al.  Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[16]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Y. Barenholz,et al.  In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. , 1992, Biochimica et biophysica acta.

[18]  P. Ravdin.  Should HER2 status be routinely measured for all breast cancer patients? , 1999, Seminars in oncology.

[19]  John W. Park,et al.  Development of anti-p185HER2 immunoliposomes for cancer therapy. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  B Fisher,et al.  erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. , 1998, Journal of the National Cancer Institute.

[21]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[22]  John W. Park,et al.  Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. , 1997, Biochemistry.

[23]  R. Neve,et al.  Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. , 2001, Biochemical and biophysical research communications.

[24]  M. Sliwkowski,et al.  Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers , 1999, Oncogene.

[25]  D. Papahadjopoulos,et al.  Liposomes revisited , 1995, Science.

[26]  D. Friend,et al.  Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. , 1992, Cancer research.

[27]  Y. Yarden,et al.  Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. , 1996, British Journal of Cancer.

[28]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[29]  L. Norton,et al.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.

[30]  A. Gabizon,et al.  Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. , 1989, Journal of the National Cancer Institute.

[31]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[32]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.